The bill establishes a Naloxone Purchase Trust Fund within the Commonwealth to support a universal purchase system for the distribution of opioid antagonists, specifically naloxone, aimed at reversing opioid overdoses. It amends Chapter 111 of the General Laws by inserting a new section that defines key terms related to opioid antagonists and outlines the fund's purpose, which includes covering costs associated with the purchase, storage, and distribution of these life-saving medications. The fund will consist of money transferred from the executive office of health and human services, voluntary contributions, and interest earnings, and will be managed by the commissioner of the department or a designee. The bill also stipulates that no expenditure from the fund should cause it to be in deficit at the end of a fiscal year, and any remaining balance can be carried over to subsequent years.

Additionally, the bill amends Section 64 of Chapter 118E to include a new definition for "opioid antagonist revenue amount," which reflects the estimated costs associated with the Naloxone Purchase Trust Fund. It also modifies existing definitions and provisions related to managed care organization services assessments to incorporate the opioid antagonist revenue amount. The bill requires the secretary of health and human services to seek necessary federal approvals for its implementation, and it will not take effect until these approvals are obtained.